MYRIAD GENETICS INC

For the period ended Mar 31, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of and (unaudited)

Condensed Consolidated Balance Sheets (unaudited)

	March 31,2026	December 31,2025
ASSETS
Current assets:
Cash and cash equivalents	$124.4	$149.6
Trade accounts receivable	123.8	115.3
Inventory	27.9	30.6
Prepaid taxes	2.0	12.0
Prepaid expenses and other current assets	34.7	25.1
Total current assets	312.8	332.6
Operating lease right-of-use assets	51.0	49.4
Property, plant and equipment, net	111.5	114.0
Intangible assets, net	145.7	153.4
Goodwill	47.1	51.6
Other assets	5.6	5.6
Total assets	$673.7	$706.6
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$32.6	$30.0
Accrued liabilities	90.5	96.9
Current maturities of operating lease liabilities	7.1	6.9
Total current liabilities	130.2	133.8
Long-term debt	120.3	119.9
Noncurrent operating lease liabilities	84.1	83.0
Other long-term liabilities	1.7	1.9
Total liabilities	336.3	338.6
Commitments and contingencies
Stockholders’ equity:
Common stock, 94.4 and 93.5 shares outstanding at March 31, 2026 and December 31, 2025, respectively	0.9	0.9
Additional paid-in capital	1,492.6	1,489.0
Accumulated other comprehensive income	0.7	0.8
Accumulated deficit	(1,156.8)	(1,122.7)
Total stockholders' equity	337.4	368.0
Total liabilities and stockholders’ equity	$673.7	$706.6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.